Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the ‘untreatable case’ and ‘lost cause’ from the norm to the exception.
Entheon is committed to the legal development of regulated, safe & effective therapies, and in educating the public and medical profession as to the efficacy of psychedelic protocols when clinically administered in the optimum set and setting.
Stock Performance
Entheon Biomedical News 11 articles
- Entheon Announces Agreement to Acquire Mentis AI
- Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical
- Cybin Acquires DMT Clinical Study from Entheon Biomedical
- Entheon Biomedical Announces the Approval of DMT Clinical Trial
- Entheon Biomedical Announces EEG Patent Application & Provides Research Update
- Entheon Biomedical Corp. Acquires Lobo Genetics Inc.
- Entheon Biomedical Corp. Launches Psychedelics Genetic Test
- Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch
- Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific
- Entheon Biomedical to Begin Trading on the Frankfurt Exchange
- Entheon Biomedical Corp. Commences Trading on the Canadian Securities Exchange